Levetiracetam Altan Pharma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This interaction stabilises neuronal firing and reduces hyper‑excitability, helping to prevent the spread of seizure activity without directly influencing ion channels or GABA receptors.

The specific dose of Levetiracetam Altan Pharma is determined by the treating physician based on the patient’s age, weight, renal function, and clinical response. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimizing adverse effects.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Breastfeeding decisions should be made after consulting a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levetiracetam offers a distinct mechanism (SV2A binding) and a relatively favorable interaction profile compared with enzyme‑inducing agents such as carbamazepine or phenytoin. It is often chosen for patients who need rapid intravenous administration or who have experienced side‑effects with older agents.

Levetiracetam intravenous solution should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and discard any solution that appears discoloured or contains particles.

Levetiracetam is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and total daily dose are prescribed by the treating physician and may be adjusted according to clinical response and renal function.

Serious adverse events include severe allergic reactions (rash, swelling, breathing difficulty), significant mood or behavior changes such as depression or suicidal thoughts, and hematologic abnormalities like neutropenia or thrombocytopenia. Prompt medical attention is required if any of these occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking medications that markedly reduce levetiracetam plasma levels.